Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Tumor necrosis factor and tuberculosis.

Lin PL, Plessner HL, Voitenok NN, Flynn JL.

J Investig Dermatol Symp Proc. 2007 May;12(1):22-5. Review.

2.

Reactivation of tuberculosis by tumor necrosis factor neutralization.

Jacobs M, Samarina A, Grivennikov S, Botha T, Allie N, Fremond C, Togbe D, Vasseur V, Rose S, Erard F, Monteiro A, Quesniaux V, Ryffel B.

Eur Cytokine Netw. 2007 Mar;18(1):5-13. Epub 2007 Mar 30. Review.

3.

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.

Keane J.

Rheumatology (Oxford). 2005 Jun;44(6):714-20. Epub 2005 Mar 1. Review.

PMID:
15741198
4.

Life and death in the granuloma: immunopathology of tuberculosis.

Saunders BM, Britton WJ.

Immunol Cell Biol. 2007 Feb-Mar;85(2):103-11. Epub 2007 Jan 9. Review.

PMID:
17213830
5.

Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside.

Xie X, Li F, Chen JW, Wang J.

J Microbiol Immunol Infect. 2014 Aug;47(4):268-74. doi: 10.1016/j.jmii.2013.03.005. Epub 2013 May 30. Review.

6.

Chemokines and tuberculosis.

Algood HM, Chan J, Flynn JL.

Cytokine Growth Factor Rev. 2003 Dec;14(6):467-77. Review.

PMID:
14563349
7.

Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.

Wallis RS.

J Investig Dermatol Symp Proc. 2007 May;12(1):16-21. Review.

8.

TNF in host resistance to tuberculosis infection.

Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedospasov SA, Garcia I, Olleros ML, Shebzukhov Y, Kuprash D, Vasseur V, Rose S, Court N, Vacher R, Ryffel B.

Curr Dir Autoimmun. 2010;11:157-79. doi: 10.1159/000289204. Epub 2010 Feb 18. Review.

PMID:
20173394
9.

Foamy macrophages and the progression of the human tuberculosis granuloma.

Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F.

Nat Immunol. 2009 Sep;10(9):943-8. doi: 10.1038/ni.1781. Epub 2009 Aug 19. Review.

10.

Tumor necrosis factor alpha in mycobacterial infection.

Dorhoi A, Kaufmann SH.

Semin Immunol. 2014 Jun;26(3):203-9. doi: 10.1016/j.smim.2014.04.003. Epub 2014 May 10. Review.

PMID:
24819298
11.
12.

Why does tumor necrosis factor targeted therapy reactivate tuberculosis?

Ehlers S.

J Rheumatol Suppl. 2005 Mar;74:35-9. Review.

PMID:
15742463
13.

Infections associated with tumor necrosis factor-alpha antagonists.

Rychly DJ, DiPiro JT.

Pharmacotherapy. 2005 Sep;25(9):1181-92. Review.

PMID:
16164393
14.

Role of tumor necrosis factor-alpha in disease states and inflammation.

Strieter RM, Kunkel SL, Bone RC.

Crit Care Med. 1993 Oct;21(10 Suppl):S447-63. Review.

PMID:
8403983
15.

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.

Wallis RS.

Lancet Infect Dis. 2008 Oct;8(10):601-11. doi: 10.1016/S1473-3099(08)70227-5. Review.

PMID:
18922482
16.

Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view.

Paige C, Bishai WR.

Cell Microbiol. 2010 Mar;12(3):301-9. doi: 10.1111/j.1462-5822.2009.01424.x. Epub 2009 Dec 21. Review.

PMID:
20039878
17.

[Infectious complications associated with the use of tumor necrosis factor antagonist drugs: a review].

García-Lechuz Moya JM.

Enferm Infecc Microbiol Clin. 2005 Nov;23(9):551-9. Review. Spanish.

PMID:
16324568
18.

TNF-alpha blockade and tuberculosis: better look before you leap.

Arend SM, Breedveld FC, van Dissel JT.

Neth J Med. 2003 Apr;61(4):111-9. Review.

19.

Key issues in the diagnosis and management of tuberculosis.

Milburn H.

J R Soc Med. 2007 Mar;100(3):134-41. Review. No abstract available. Erratum in: J R Soc Med. 2007 Apr;100(4):165.

20.

The Koch phenomenon and the immunopathology of tuberculosis.

Rook GA, Stanford JL.

Curr Top Microbiol Immunol. 1996;215:239-62. Review. No abstract available.

PMID:
8791717

Supplemental Content

Support Center